Clinical trials have demonstrated that ADCs significantly prolong progression-free and overall survival in patients with HER2-low tumors (1+ or IHC 2+ without amplification), which account for approximately 45–64% of all breast cancers [1,2,3]. Here, ERBB2 is linked to breast carcinoma.